Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Jinlian Qingre is a traditional Chinese herbal medicine formulation used primarily for the treatment of respiratory infections such as the common cold and hand, foot, and mouth disease (HFMD). It is available in several dosage forms including effervescent tablets, granules, and capsules. The formulation contains plant-derived ingredients with heat-clearing and detoxifying properties according to traditional Chinese medicine theory. Clinical studies have shown that when combined with conventional therapy for uncomplicated HFMD in children, it can significantly reduce fever duration and accelerate healing of skin or oral mucosa lesions without significant adverse effects. The product is recommended by health authorities in China as a control measure for mild HFMD[3]. Its mechanism of action is not fully elucidated but likely involves anti-inflammatory and antiviral effects attributed to its herbal components[1][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Jinlian Qingre.